Edition:
United States

Delcath Systems Inc (DCTH.OQ)

DCTH.OQ on NASDAQ Stock Exchange Capital Market

1.98USD
7 Dec 2016
Change (% chg)

-- (--)
Prev Close
$1.98
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
16,987
52-wk High
$9.44
52-wk Low
$1.38

DCTH.OQ

Chart for DCTH.OQ

About

Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System... (more)

Overall

Beta: 2.27
Market Cap(Mil.): $4.35
Shares Outstanding(Mil.): 2.20
Dividend: --
Yield (%): --

Financials

  DCTH.OQ Industry Sector
P/E (TTM): -- 31.03 30.77
EPS (TTM): -10.07 -- --
ROI: -112.21 13.42 15.23
ROE: -161.99 17.11 16.56

BRIEF-Delcath Q3 loss $0.66/shr

* Believes it has sufficient capital to fund its operating activities through end of 2017

Nov 11 2016

BRIEF-Delcath Systems issues letter to stockholders

* Assuming conditions are satisfied, expect anticipated qtrly releases throughout 2017 will fund clinical development plan through 2017-end Source text for Eikon: Further company coverage:

Oct 18 2016

BRIEF-Delcath Systems announces new clinical sites for FOCUS Phase 3 trial for ocular melanoma liver metastases

* Delcath Systems - 5 new clinical trial sites in U.S. have been activated in global FOCUS Phase 3 clinical trial for ocular melanoma liver metastases

Oct 11 2016

BRIEF-Delcath prices underwritten public offering at $3.00 per share

* Delcath prices underwritten public offering of common stock and warrants

Sep 30 2016

BRIEF-Delcath announces proposed public offering of common stock and warrants

* Delcath announces proposed public offering of common stock and warrants

Sep 29 2016

BRIEF-Delcath posts Q2 loss of $4.41/share

* Delcath believes it has sufficient capital to fund its operating activities through end of 2017 Source text for Eikon: Further company coverage:

Aug 16 2016

Earnings vs. Estimates